---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-016468"
form_type: "8-K"
ticker: "ETON"
cik: "0001710340"
company_name: "Eton Pharmaceuticals, Inc."
filed_at: "2025-05-13T23:59:59+00:00"
generated_at: "2026-05-21T16:34:30.501165+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Eton Q1 revenue $17.3M (+117% YoY); product sales $14.0M (+76%); Non-GAAP EPS $0.07; Adjusted EBITDA $3.7M

## Summary
- Q1 2025 product sales $14.0M, 76% growth YoY; 17th straight quarter of sequential growth.
- GAAP net loss $(0.06) per share; Non-GAAP EPS $0.07; Adjusted EBITDA $3.7M.
- Relaunched INCRELEX (ultra-rare pediatric endocrinology) and GALZIN (Wilson disease); ET-400 NDA PDUFA May 28.
- Submitted NDA for ET-600 (desmopressin oral solution) after positive pivotal study; expects 10-month FDA review.
- Cash $17.4M; generated $2.1M operating cash flow; expects to exit 2025 at ~$80M annual revenue run rate.

## SEC filing metadata
- accession: 0001437749-25-016468
- form_type: 8-K
- ticker: ETON
- cik: 0001710340
- company_name: Eton Pharmaceuticals, Inc.
- filed_at: 2025-05-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1710340/000143774925016468/0001437749-25-016468-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1710340/000143774925016468/eton20250502_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-016468
- JSON: https://secwatch.observer/filing/0001437749-25-016468.json
- Plain text: https://secwatch.observer/filing/0001437749-25-016468.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.